Vaccination with Ad5 vectors expands Ad5-specific CD8+ T cells without altering memory phenotype or functionality

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Hutnick, Natalie A ^a   Carnathan, Diane G ^a   Dubey, Sheri A ^b   Cox, Kara S ^b   Kierstead, Lisa ^b   Makadonas, George ^a   Ratcliffe, Sarah J ^a   Lasaro, Marcio O ^c   Robertson, Michael N ^b   Casimiro, Danilo R ^b   Ertl, Hildegund C J ^c   Betts, Michael R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NEUTRALIZING ANTIBODY; PERFORIN;

ADENOVIRUS 5; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL STRAIN HEK293; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; PHENOTYPE; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BIOLOGICAL MODEL; CHO CELL; CRICETULUS; CYTOLOGY; GENE VECTOR; GENETICS; HAMSTER; METHODOLOGY; MONONUCLEAR CELL; TIME;

HUMAN ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHO CELLS; CLINICAL TRIALS AS TOPIC; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; PHENOTYPE; TIME FACTORS;

EID: 78650982702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014385     Document Type: Article

References (33)

1. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, et al. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46: 1769-1781.
2. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replicationincompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 415: 331-335.
3. Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, et al. (2004) Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78: 11434-11438.
4. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, et al. (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305-6313.
5. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, et al. (2009) Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 25: 103-114.
6. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
7. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, et al. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77: 799-803.
8. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, et al. (2004) Neutralizing antibodies and CD8 + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78: 2666-2673.
9. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
10. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
11. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, et al. (2001) Replicationdefective vector based on a chimpanzee adenovirus. J Virol 75: 11603-11613.
12. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing antivector immunity. Nature 441: 239-243.
13. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, et al. (2008) Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82: 546-554.
14. Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, et al. (2009) Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 83: 2623-2631.
15. Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, et al. (2009) Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 83: 6318-6322.
16. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV- 1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
17. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, et al. Adenovirus-specific human T cells are pervasive, polyfunctional, and crossreactive. Vaccine 28: 1932-1941.
18. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, et al. (2009) Adenovirusspecific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15: 873-875.
19. Hutnick LK, Huang X, Loo TC, Ma Z, Fan G Repression of retrotransposal elements in mouse embryonic stem cells is primarily mediated by DNA methylation-independent mechanism. J Biol Chem.
20. Xiang ZQ, Yang Y, Wilson JM, Ertl HC (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219: 220-227.
21. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
22. Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC (2005) Antitumor DNA vaccines based on the expression of human papillomavirus-16 E6/ E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect 7: 1541-1550.
23. Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN, et al. (1994) Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 371: 802-806.
24. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, et al. (2004) Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15: 293-304.
25. Steinwaerder DS, Carlson CA, Lieber A (2000) DNA replication of firstgeneration adenovirus vectors in tumor cells. Hum Gene Ther 11: 1933-1948.
26. Spergel JM, Chen-Kiang S (1991) Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc Natl Acad Sci U S A 88: 6472-6476.
27. Sridhar S, Reyes-Sandoval A, Draper SJ, Moore AC, Gilbert SC, et al. (2008) Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 82: 3822-3833.
28. Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, et al. (2008) RBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 3: e3790.
29. Krebs JW, Long-Marin SC, Childs JE (1998) Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manag Pract 4: 56-62.
30. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirusinfected hepatocytes in vivo. Gene Ther 3: 137-144.
31. Hensley SE, Giles-Davis W, McCoy KC, Weninger W, Ertl HC (2005) Dendritic cell maturation, but not CD8 + T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 175: 6032-6041.
32. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, et al. (2007) Adenoviral vectors persist in vivo and maintain activated CD8 + T cells: implications for their use as vaccines. Blood 110: 1916-1923.
33. Prasad SA, Norbury CC, Chen W, Bennink JR, Yewdell JW (2001) Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol 166: 4809-4812.